Oncorus, Inc. (NASDAQ:ONCR) Sees Significant Increase in Short Interest

Oncorus, Inc. (NASDAQ:ONCR – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 31.9% from the April 15th total of 780,800 shares. Based on an average trading volume of 138,600 shares, the days-to-cover ratio is presently 7.4 days. Currently, 6.4% of the company’s stock are short sold.

Shares of NASDAQ:ONCR traded down $0.05 during midday trading on Wednesday, hitting $1.24. The stock had a trading volume of 874 shares, compared to its average volume of 131,717. The company has a market capitalization of $32.09 million, a PE ratio of -0.48 and a beta of 4.26. The stock has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $3.69. Oncorus has a 1 year low of $1.03 and a 1 year high of $17.79.

Oncorus (NASDAQ:ONCR – Get Rating) last issued its earnings results on Wednesday, May 4th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.08. Equities analysts forecast that Oncorus will post -2.66 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. boosted its holdings in Oncorus by 151.6% during the fourth quarter. Citigroup Inc. now owns 5,860 shares of the company’s stock worth $31,000 after buying an additional 3,531 shares in the last quarter. NEXT Financial Group Inc purchased a new stake in Oncorus during the fourth quarter worth about $40,000. Wells Fargo & Company MN purchased a new stake in Oncorus during the fourth quarter worth about $47,000. Acadian Asset Management LLC purchased a new stake in Oncorus during the fourth quarter worth about $54,000. Finally, Parametric Portfolio Associates LLC acquired a new position in Oncorus during the fourth quarter worth about $72,000. 84.26% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on the stock. Maxim Group lowered their price objective on shares of Oncorus from $20.00 to $7.00 in a research report on Thursday, March 10th. HC Wainwright assumed coverage on shares of Oncorus in a research report on Monday, March 28th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Oncorus from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Wednesday, May 11th.

About Oncorus (Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Featured Stories